Dian Diagnostics Group Co.,Ltd.

SZSE:300244 Stock Report

Market Cap: CN¥8.7b

Dian Diagnostics GroupLtd Valuation

Is 300244 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300244 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300244 (CN¥14.1) is trading below our estimate of fair value (CN¥44.35)

Significantly Below Fair Value: 300244 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300244?

Other financial metrics that can be useful for relative valuation.

300244 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA11.2x
PEG Ratio0.9x

Price to Earnings Ratio vs Peers

How does 300244's PE Ratio compare to its peers?

The above table shows the PE ratio for 300244 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.2x
600682 Nanjing Xinjiekou Department Store
20.5x30.4%CN¥7.7b
002044 Meinian Onehealth Healthcare Holdings
44x50.3%CN¥17.2b
300962 Zhongjin Irradiation
36.7xn/aCN¥4.0b
301103 Liaoning He Eye Hospital Group
111.6xn/aCN¥4.0b
300244 Dian Diagnostics GroupLtd
51.3x57.3%CN¥8.7b

Price-To-Earnings vs Peers: 300244 is good value based on its Price-To-Earnings Ratio (51.3x) compared to the peer average (53.2x).


Price to Earnings Ratio vs Industry

How does 300244's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300244 is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the CN Healthcare industry average (32.9x).


Price to Earnings Ratio vs Fair Ratio

What is 300244's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300244 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.3x
Fair PE Ratio43.1x

Price-To-Earnings vs Fair Ratio: 300244 is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the estimated Fair Price-To-Earnings Ratio (43.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300244 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥14.10
CN¥27.31
+93.7%
24.6%CN¥40.00CN¥18.50n/a8
Apr ’25CN¥18.14
CN¥29.08
+60.3%
17.0%CN¥40.00CN¥22.48n/a8
Mar ’25CN¥19.25
CN¥29.67
+54.1%
16.9%CN¥40.00CN¥22.48n/a7
Feb ’25CN¥17.42
CN¥30.84
+77.0%
13.2%CN¥40.00CN¥27.00n/a7
Jan ’25CN¥23.81
CN¥31.13
+30.7%
12.4%CN¥40.00CN¥27.98n/a7
Dec ’24CN¥26.58
CN¥31.13
+17.1%
12.4%CN¥40.00CN¥27.98n/a7
Nov ’24CN¥22.76
CN¥33.71
+48.1%
16.0%CN¥43.04CN¥28.00n/a7
Oct ’24CN¥23.50
CN¥35.02
+49.0%
14.3%CN¥43.04CN¥29.00n/a7
Sep ’24CN¥22.67
CN¥36.45
+60.8%
15.0%CN¥45.00CN¥29.00n/a7
Aug ’24CN¥23.87
CN¥37.77
+58.3%
11.4%CN¥45.00CN¥32.00n/a7
Jul ’24CN¥25.63
CN¥37.77
+47.4%
11.4%CN¥45.00CN¥32.00n/a7
Jun ’24CN¥25.50
CN¥37.77
+48.1%
11.4%CN¥45.00CN¥32.00n/a7
May ’24CN¥27.08
CN¥40.58
+49.8%
22.6%CN¥60.00CN¥32.00CN¥14.107
Apr ’24CN¥28.65
CN¥42.62
+48.8%
22.1%CN¥60.00CN¥32.00CN¥18.146
Mar ’24CN¥26.49
CN¥42.62
+60.9%
22.1%CN¥60.00CN¥32.00CN¥19.256
Feb ’24CN¥27.27
CN¥43.12
+58.1%
21.0%CN¥60.00CN¥32.00CN¥17.426
Jan ’24CN¥25.13
CN¥45.12
+79.5%
16.4%CN¥60.00CN¥38.00CN¥23.816
Dec ’23CN¥27.47
CN¥45.79
+66.7%
15.2%CN¥60.00CN¥38.00CN¥26.586
Nov ’23CN¥28.59
CN¥45.80
+60.2%
15.2%CN¥60.00CN¥38.00CN¥22.766
Oct ’23CN¥29.02
CN¥45.50
+56.8%
18.7%CN¥60.00CN¥38.00CN¥23.504
Sep ’23CN¥31.20
CN¥45.50
+45.8%
18.7%CN¥60.00CN¥38.00CN¥22.674
Aug ’23CN¥30.98
CN¥46.75
+50.9%
17.7%CN¥60.00CN¥38.00CN¥23.874
Jul ’23CN¥30.62
CN¥48.50
+58.4%
14.2%CN¥60.00CN¥42.00CN¥25.634
Jun ’23CN¥29.94
CN¥51.25
+71.2%
15.3%CN¥60.00CN¥42.00CN¥25.504
May ’23CN¥32.69
CN¥51.25
+56.8%
15.3%CN¥60.00CN¥42.00CN¥27.084

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.